Literature DB >> 18664725

[The strategic plan for preparedness and response to bioterrorism in Korea].

Hyun Soon Hwang1.   

Abstract

Following the Anthrax bioterrorism attacks in the US in 2001, the Korean government established comprehensive countermeasures against bioterrorism. These measures included the government assuming management of all infectious agents that cause diseases, including smallpox, anthrax, plaque, botulism, and the causative agents of viral hemorrhagic fevers (ebola fever, marburg fever, and lassa fever) for national security. In addition, the Korean government is reinforcing the ability to prepare and respond to bioterrorism. Some of the measures being implemented include revising the laws and guidelines that apply to the use of infectious agents, the construction and operation of dual surveillance systems for bioterrorism, stockpiling and managing products necessary to respond to an emergency (smallpox vaccine, antibiotics, etc.) and vigorously training emergency room staff and heath workers to ensure they can respond appropriately. In addition, the government's measures include improved public relations, building and maintaining international cooperation, and developing new vaccines and drugs for treatments of infectious agents used to create bioweapons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664725     DOI: 10.3961/jpmph.2008.41.4.209

Source DB:  PubMed          Journal:  J Prev Med Public Health        ISSN: 1975-8375


  2 in total

1.  A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.

Authors:  Cheryl X Zhang; Christian Sauder; Tahir Malik; Steven A Rubin
Journal:  Biologicals       Date:  2009-11-06       Impact factor: 1.856

2.  Network Experiences from a Cross-Sector Biosafety Level-3 Laboratory Collaboration: A Swedish Forum for Biopreparedness Diagnostics.

Authors:  Johanna Thelaus; Anna Lindberg; Susanne Thisted Lambertz; Mona Byström; Mats Forsman; Hans Lindmark; Rickard Knutsson; Viveca Båverud; Andreas Bråve; Pontus Jureen; Annelie Lundin Zumpe; Öjar Melefors
Journal:  Health Secur       Date:  2017-08-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.